Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease at Clinical Trials on Alzheimer’s Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html
van Dyck, H., et al. Lecanemab in Early Alzheimer¡¯s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.
Department of Health – Press Release ¡°Dementia Care Seminar cum Kick-off Ceremony for Dementia Care Campaign. Available at: https://www.dh.gov.hk/english/press/2006/061013.html
Ruby Yu , et al. Trends in Prevalence and Mortality of Dementia inElderly Hong Kong Population: Projections, Disease Burden, andImplications for Long-Term Care. Int J Alzheimer¡¯s Dis. 2012(7593):406852. doi: 10.1155/2012/406852
Amin L, Harris DA. A¦Â receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z
Ono K, Tsuji M. Protofibrils of Amyloid-¦Â are Important Targets of a Disease-Modifying Approach for Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.